What Is Thrombotic Thrombocytopenic Purpura?

Thrombotic thrombocytopenic purpura, or TTP, is a rare and life-threatening blood disorder in which tiny clots form throughout the body’s small blood vessels, consuming platelets and shredding red blood cells in the process. The underlying problem is a severe shortage of an enzyme called ADAMTS13, which normally keeps a sticky clotting protein called von Willebrand factor (VWF) trimmed to a safe size. Without enough of that enzyme, oversized strands of VWF accumulate, snag passing platelets, and plug up the microvasculature. Left untreated, TTP is rapidly fatal, but modern treatment has pushed survival above 80%.

What Goes Wrong in the Blood

The core of TTP is a broken maintenance system. VWF is a protein released by the cells lining blood vessels. When freshly secreted, it comes out in ultra-large multimers, long molecular chains that are exceptionally good at grabbing platelets. Under normal circumstances, the enzyme ADAMTS13 clips these chains into smaller, less reactive pieces within seconds to minutes on the endothelial surface under flowing blood conditions.¹ This is a zinc-containing metalloprotease, meaning it uses a zinc atom at its active site to cut VWF.²

When ADAMTS13 activity drops below roughly 10% of normal, the ultra-large VWF multimers accumulate. These strands spontaneously latch onto a receptor on platelets, pulling them out of circulation and forming microthrombi throughout the small blood vessels.³ The consequences cascade: platelet counts plummet (thrombocytopenia) because the platelets are being consumed in clots; red blood cells are mechanically torn apart as they squeeze past the obstructions (hemolytic anemia); and organ tissues downstream of the blockages suffer damage from reduced blood flow.

Immune TTP Versus the Inherited Form

TTP comes in two broad categories. The far more common form is immune TTP (iTTP), in which a person’s own immune system produces antibodies against ADAMTS13. These autoantibodies either block the enzyme’s activity directly or accelerate its clearance from the bloodstream. Nearly all inhibitory antibodies target a specific region of the enzyme called the spacer domain.⁴ Immune TTP can strike at any age but typically appears in adulthood. It tends to come on suddenly, sometimes triggered by infection, pregnancy, or certain medications, and it can relapse.

The inherited form, known as congenital TTP or Upshaw-Schulman syndrome, is caused by genetic mutations in the ADAMTS13 gene itself. Mutations have been found throughout the gene, and the condition is inherited in a pattern that requires a defective copy from each parent.⁵ Because people with congenital TTP are born with severely reduced ADAMTS13 activity, their first acute episode can occur in childhood, though pregnancy or infection often serves as the trigger that tips them over the edge for the first time. Congenital TTP is much rarer than the immune form and tends to follow a different clinical course, with acute episodes often tied to identifiable physiological stresses.

Symptoms and How They Present

For decades, doctors were taught to look for a “classic pentad” of five symptoms: fever, low platelets, hemolytic anemia, neurological problems, and kidney failure. In practice, all five appear together in fewer than one in ten patients with confirmed TTP.⁶ Waiting for the full pentad before suspecting TTP would mean dangerous delays. The modern approach is to act on a combination of low platelets and hemolytic anemia with fragmented red blood cells visible on a blood smear, rather than waiting for the remaining features.

Brain involvement is the most common serious complication. In studies of patients with blood-vessel clotting disorders like TTP, neurological symptoms appeared in roughly 85% of cases, and many were severe: confusion, seizures, personality changes, stroke, and in the worst situations, coma.⁷ Even in patients who survive the acute episode and achieve blood-count remission, brain imaging shows evidence of small-vessel injury in a substantial proportion. One study found signs of small-vessel brain disease in about half of iTTP patients during their acute episode, compared to about a quarter of matched controls, and the damage progressed over the first year despite the blood counts returning to normal.⁸

Getting to a Diagnosis Quickly

Speed matters enormously. Untreated immune TTP is rapidly fatal, so treatment usually begins before confirmatory lab results come back.⁹ The definitive laboratory finding is ADAMTS13 activity below 10%, which confirms TTP in the right clinical setting.¹⁰ Older lab methods required hours to days for a result, but newer rapid assays can deliver an answer in about half an hour. A large meta-analysis of these rapid tests found that the leading automated assay had a sensitivity of 98% and a specificity of 99% for identifying severe ADAMTS13 deficiency.¹¹

When rapid ADAMTS13 testing is unavailable, clinicians can use a clinical scoring system called the PLASMIC score. It uses seven routine lab values and clinical features to estimate the likelihood of severe ADAMTS13 deficiency. The score was validated with strong accuracy, and it outperformed standard clinical judgment alone.¹² There is an important caveat: the PLASMIC score becomes less reliable in patients over 60, where its sensitivity and specificity both drop. Older adults with TTP can be missed by scoring systems, so clinicians treating elderly patients with unexplained blood-count abnormalities need a higher index of suspicion.¹³

Conditions That Look Alarmingly Similar

One of the trickiest aspects of TTP is that several other conditions produce nearly identical blood-count abnormalities and organ damage. Atypical hemolytic uremic syndrome (aHUS), caused by overactivation of the complement immune system, creates the same picture of low platelets, shredded red cells, and organ injury. Historically doctors separated them by which organs took the biggest hit — brain for TTP, kidneys for aHUS — but the overlap is large enough that clinical features alone often cannot distinguish them.¹⁴ Getting it right matters because the treatments differ: plasma exchange is the backbone of TTP therapy but is far less effective in aHUS, which responds dramatically to complement-blocking drugs.

Pregnancy complicates the picture further. Severe HELLP syndrome (a dangerous complication of preeclampsia involving hemolysis, elevated liver enzymes, and low platelets) can be almost impossible to distinguish from TTP on clinical grounds alone. Misdiagnosing TTP as HELLP and simply delivering the baby without starting plasma exchange can be fatal.¹⁵ The definitive separator is ADAMTS13 activity: an undetectable level points to TTP. When that test is unavailable, clues favoring TTP over HELLP include more pronounced hemolysis, neurological involvement, and the absence of disseminated intravascular coagulation.¹⁶

Pregnancy as a Trigger

Pregnancy is one of the most common triggers for TTP, accounting for roughly 12–25% of adult-onset cases.¹⁷ A large French registry tracked over 1,100 patients with pregnancy-onset blood-vessel clotting problems and found that about 9% had confirmed TTP. Among women of childbearing age diagnosed with TTP, roughly one in five had their episode triggered by pregnancy. The breakdown by subtype was revealing: about half had the immune form, about a quarter had congenital TTP unmasked for the first time by pregnancy, and another quarter had a less well-characterized form.¹⁸

These subtypes behave differently in future pregnancies. The immune form carries a relapse risk that is not limited to subsequent pregnancies; it can come back at any time. Congenital TTP, on the other hand, almost always requires pregnancy as the specific trigger, and women with this form typically need preventive plasma therapy during future pregnancies.¹⁹ Recent research into the pathophysiology of pregnancy-associated blood-clotting disorders has also highlighted a vicious cycle between overactivated immune cells called neutrophils and the complement system, where each amplifies the other’s harmful effects.²⁰

Drug-Induced Cases

Certain medications can trigger a related condition known as drug-induced thrombotic microangiopathy. These cases split into two categories: an immune-mediated type, where the drug provokes antibody production that damages blood vessels and platelets, and a dose-related toxic type tied directly to how much of the drug accumulates in the body.²¹ The immune-mediated form can look clinically identical to classic TTP and typically requires stopping the offending drug. Various chemotherapy agents, immunosuppressants, and antiplatelet drugs have been implicated. Recognizing a drug trigger can change management considerably, because plasma exchange may be less effective when the drug itself is the ongoing cause of the problem.

How TTP Is Treated

The cornerstone of treatment for immune TTP has been therapeutic plasma exchange since a landmark Canadian trial established it as the gold standard in the early 1990s. Before plasma exchange existed, TTP was nearly universally fatal. Daily plasma exchange transformed survival rates to around 80–85%.²² The procedure works by physically removing the harmful anti-ADAMTS13 antibodies and the ultra-large VWF multimers from the blood while replacing the missing enzyme from donor plasma.

On top of plasma exchange, two major additions have reshaped treatment in the past decade. Rituximab, a drug that depletes the B cells responsible for making the harmful antibodies, is now considered standard of care for immune TTP.²³ It has been clearly effective at achieving remission, though whether giving it during the acute episode reduces the relapse rate over the long term remains debated; at least one analysis found no significant reduction in acute relapses from rituximab given during the initial bout.²⁴

Caplacizumab, approved in 2019, was the first drug designed specifically for TTP. It is a nanobody — a type of miniaturized antibody fragment — that blocks the interaction between ultra-large VWF multimers and platelets.²⁵ Structural studies have shown that caplacizumab does not simply elbow platelets out of the way; instead it locks VWF into a shape that platelets cannot adhere to.²⁶ By stopping platelet consumption almost immediately, caplacizumab shortens the time to platelet-count recovery and reduces the need for plasma exchange sessions. The tradeoff is cost: adding caplacizumab to standard treatment carries an incremental cost of roughly $47,000 per patient from a hospital perspective, though it also cuts hospitalization and plasma-exchange expenses.²⁷ A cost-effectiveness analysis estimated a gain of about three additional life-years and just under two quality-adjusted life-years per patient, with an incremental cost-effectiveness ratio of about $146,000 per quality-adjusted life-year gained.²⁸

Monitoring After Remission and the Relapse Problem

Surviving an acute TTP episode is not the end of the story. Immune TTP can relapse, sometimes years later, and the risk is driven by the return of autoantibodies and falling ADAMTS13 activity. Current expert recommendations call for checking ADAMTS13 activity every three months after remission.²⁹ When activity begins to drop — even before symptoms appear — preemptive rituximab can be given to knock back the emerging antibody response before it triggers another crisis. This approach has been effective at preventing clinical relapses and represents a shift from reactive treatment to proactive surveillance.

For congenital TTP, which lacks an autoimmune component, prevention takes a different form: regular infusions of plasma or plasma-derived products to replace the missing enzyme. Recombinant human ADAMTS13 (a lab-manufactured version of the enzyme) has recently emerged as a promising alternative. In a study of 39 patients receiving recombinant ADAMTS13 prophylaxis, the treatment significantly improved relapse-free survival with fewer adverse events compared to plasma-derived products.³⁰ This represents a meaningful step forward because plasma infusions carry risks of allergic reactions and volume overload, and standardizing dosing has always been difficult.

Life After TTP

Perhaps the least appreciated aspect of TTP is what happens to survivors long after the blood counts normalize. The disease leaves a trail of damage that extends well beyond the acute episode. In one survey, 68% of TTP survivors reported depression, and their cognitive test scores were considerably lower than those of healthy controls.³¹ A separate study found persisting problems with memory and attention, along with anxiety in about 20% and depression in about 43% of patients in remission, accompanied by generally reduced quality of life.³²

Beyond the neuropsychological toll, TTP survivors face increased cardiovascular risk. Hypertension and ischemic events appear at higher rates in this population, likely related to cumulative microvascular damage during acute episodes.³³ The small-vessel brain damage documented on imaging, which progresses even during apparent remission, may be a structural correlate of these cognitive and mood symptoms. For survivors, this means that “recovery” in the blood-count sense does not equal recovery in the neurological or psychological sense. Screening for depression, cognitive difficulties, and cardiovascular risk factors should be part of routine follow-up care, though in practice many hematology clinics are still catching up to this reality.

What Survivors and Families Should Know

If you or someone close to you has been diagnosed with TTP, a few practical points are worth keeping in mind. First, any unexplained episode of severe fatigue, confusion, bruising, or dark urine — especially in someone with a history of TTP — warrants urgent medical attention, because these could signal a relapse. Second, the monitoring schedule matters: regular ADAMTS13 checks are not bureaucratic box-ticking but a genuinely useful early-warning system. Third, mental health symptoms after TTP are common and are part of the disease, not a sign of personal weakness. Asking your hematologist about neuropsychological screening is reasonable, and seeking treatment for depression or anxiety after TTP is entirely appropriate. Finally, for women of childbearing age with a history of TTP, future pregnancies carry real risks, and preconception planning with both a hematologist and a high-risk obstetrician is strongly advised.